Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2022-01-19 Governance Information
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
累积投票制度实施细则
Governance Information Classification · 95% confidence The document is an announcement from Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding the implementation details of a cumulative voting system for electing directors and supervisors. It includes detailed rules and procedures for the voting system, the responsibilities of the board, and disclosure obligations. The document is not a financial report, earnings release, or management discussion. It is a regulatory announcement related to corporate governance procedures but does not announce changes in board members or senior management directly. It is not a proxy solicitation or voting results declaration either. Given the detailed governance-related content about voting procedures and board election rules, this fits best under Governance Information (CGR). The document length is 2552 characters, which is sufficient for a detailed governance report rather than a brief announcement. Therefore, the classification is CGR with high confidence.
2022-01-19 Chinese
利润分配管理制度
Regulatory Filings Classification · 95% confidence The document is titled as a 'Profit Distribution Management System' of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the company's profit distribution policies, procedures, and governance, including dividend distribution principles, decision-making processes, and supervisory mechanisms. It is a formal announcement of the company's internal policy regarding profit distribution, not a financial report or earnings release. The document is relatively short (3170 characters) and does not contain financial statements or results but rather a policy framework. This fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about company policy and governance related to profit distribution, not an actual report or dividend notice.
2022-01-19 Chinese
信息披露管理制度
Governance Information Classification · 95% confidence The document is titled as an "Information Disclosure Management System" of Guangdong Yongshun Biological Pharmaceutical Co., Ltd. It details the company's internal policies and procedures for information disclosure, including definitions, responsibilities, timing, and content of periodic and temporary reports, as well as compliance with relevant laws and regulations. It does not contain actual financial statements, audit results, or specific financial data. Instead, it is a governance document outlining the company's information disclosure rules and management practices. Therefore, it fits best under Governance Information (CGR). The document length (11,873 characters) and detailed procedural content support this classification rather than a simple announcement or a financial report.
2022-01-19 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the company's internal governance rules regarding related party transactions, including definitions, decision-making authority, procedures for review and approval by the board and shareholders, disclosure requirements, and compliance with relevant laws and stock exchange rules. There is no financial data, earnings information, or audit results. The document is a governance policy or internal rules document rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length (7195 characters) and detailed content support this classification with high confidence.
2022-01-19 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled as an internal governance document regarding the 'Independent Director Work System' of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the roles, responsibilities, nomination, election, and duties of independent directors, referencing relevant laws and regulations. It is a governance-related policy document rather than a financial report, earnings release, or announcement of voting results. There is no indication of financial data, audit results, or meeting presentations. The document is a detailed governance framework, fitting the description of Governance Information (CGR). The document length is about 4981 characters, which is sufficient for a full governance report rather than a brief announcement. Therefore, the classification is CGR with high confidence.
2022-01-19 Chinese
投资者关系管理办法
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management Measures" issued by Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the company's internal policies and procedures for managing investor relations, including communication principles, responsibilities, and organizational structure. It references compliance with laws and stock exchange rules but does not contain financial statements, earnings data, or audit information. It is a governance-related document outlining internal rules and practices for investor relations management. Therefore, it fits best under Governance Information (CGR). The document length (6305 characters) and content confirm it is a full policy document, not a brief announcement or a report publication notice.
2022-01-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.